NM
NMTRQ.US 9 Meters Biopharma Inc.
- Market cap
- USD 1.45K
- P/E
- -
- P/B
- 4.58x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2023.
Is NMTRQ.US undervalued?
Graham numberThe Graham number of 9 Meters Biopharma Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
9 Meters Biopharma Inc. fundamental analysis
No fundamental analysis for 9 Meters Biopharma Inc. yet.
9 Meters Biopharma Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About 9 Meters Biopharma Inc.
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity an…
Full company profile9 Meters Biopharma Inc. financial statements
2023 annualized: Fiscal year 2023 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2023, the balance sheet is the latest quarter. Figures change when the annual report is published.
9 Meters Biopharma Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -24.3M | -21.5M | -31.7M | -42.0M | -51.1M |
| EBITDA | -25.2M | -57.4M | -36.7M | -41.1M | -52.5M |
| Net Income | -27.0M | -61.5M | -36.8M | -43.8M | -55.5M |
| EPS | -14 | -6.01 | -2.85 | -3.36 | -3.87 |
| Balance Sheet | |||||
| Total Assets | 5.30M | 39.2M | 50.2M | 33.1M | 9.31M |
| Total Liabilities | 14.9M | 7.02M | 8.57M | 30.7M | 15.6M |
| Shareholders' Equity | -9.61M | 32.1M | 41.6M | 2.40M | -6.30M |
| Cash & Short-term Investments | 4.59M | 37.9M | 47.0M | 12.6M | 6.94M |
| Cash Flow | |||||
| Operating Cash Flow | -18.0M | -19.4M | -29.5M | -37.2M | -39.0M |
| Capital Expenditure | 11.9K | 2.54K | 12.5K | 2.84K | 0.00 |
| Free Cash Flow | -18.0M | -22.6M | -32.0M | -37.2M | -39.0M |
| Ratios | |||||
| ROE | - | -191.3% | -88.4% | -1,823.2% | - |
| ROA | -510.7% | -157.0% | -73.3% | -132.0% | -595.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
9 Meters Biopharma Inc. dividends
9 Meters Biopharma Inc. has not paid dividends in the last 4 fiscal years.
Last stock split: 1:20 on Oct 18, 2022.
Who owns 9 Meters Biopharma Inc.
- Insiders 0.00%
- Institutions 0.00%
- Public & others 100.00%
- Shares outstanding 14.5M
- Free float 14.2M
9 Meters Biopharma Inc. company profile
- Company name
- 9 Meters Biopharma Inc.
- Ticker
- NMTRQ.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
- Fiscal year end
- December
- Address
- 4509 Creedmoor Road, Raleigh, NC, United States, 27612
- Phone
- 919 275 1933
- Website
- 9meters.com
About 9 Meters Biopharma Inc.
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.
9 Meters Biopharma Inc. management
10- Dr. Peter H. R. Green M.D.Clinical & Scientific Advisor and Consultant
- Mr. Joseph A. Murray M.D.Clinical & Scientific Advisor and Consultant
- Dr. Ciaran P. Kelly M.D.Clinical & Scientific Advisor and Consultant
- Dr. Elena Verdu M.D., Ph.D.Clinical & Scientific Advisor and Consultant
- Mr. Markku Mäki M.D., Ph.D.Clinical & Scientific Advisor and Consultant
- Dr. William J. Sandborn M.D., Ph.D.Clinical & Scientific Advisor and Consultant · born 1964
- Dr. Roger Liddle M.D.Clinical & Scientific Advisor and Consultant
- Dr. Anthony J. Dimarino Jr.Clinical & Scientific Advisor and Consultant
- Dr. Brian Gordon Feagan FRCPC, M.D., M.P.H.Clinical & Scientific Advisor and Consultant
- Dr. Aida Habtezion M.D., M.Sc.Clinical & Scientific Advisor and Consultant